Surveillance knowledge first detected the sedative medetomidine in New York state in mid-2024, and thru 2025 it was recognized in 25.1% of opioid samples analyzed, with a month-to-month peak of 44.1% in Could 2025, in response to a Public Well being Alerts report revealed right this moment.
Medetomidine is an artificial alpha-2 adrenoreceptor agonist that may trigger extended sedation and a fancy withdrawal syndrome that may complicate group and medical responses to overdose and substance use care. The drug additionally contributed to 152 overdose deaths in 2024 and 2025, the report authors say.
Public Well being Alerts, a brand new collaboration between NEJM Proof and CIDRAP, fills a niche in dependable knowledge, providing expert-reviewed studies that translate frontline observations into actionable public well being proof. An NEJM Proof editorial explains the initiative additional.
134 medetomidine-related overdose deaths in 2025
The report outlines all samples with secondary laboratory outcomes obtainable from Could 2024 to December 2025 in New York, in addition to New York Metropolis postmortem toxicology knowledge to establish the function of the drug in deadly overdoses.
On Could 24, 2024, medetomidine was first detected in New York through laboratory testing of a sample anticipated to be heroin collected in an upstate county, which produced sudden sedative results. State officers collected further samples containing medetomidine the next month that had been concerned in two nondeadly overdoses.
Officers then alerted health workers concerning the presence of medetomidine within the illicit drug provide, which helped set up a drug customary and growth of a postmortem toxicology take a look at. Systematic postmortem toxicology testing for medetomidine started in October 2024 in New York Metropolis.
After months of laboratory detection in lower than 10% of opioid samples, medetomidine skyrocketed within the illicit drug provide, with a soar to over 20% of collected opioid samples by October 2024 and into 2025. From Could 2024 by December 2025, 25.1% of whole included opioid samples contained medetomidine, with a month-to-month peak of 44.1% of samples in Could 2025.
Loss of life certificates knowledge in New York Metropolis revealed medetomidine as a contributing reason behind 18 overdose deaths in 2024 however 134 such deaths in 2025. However the authors notice, “Trigger and method of dying for all instances in 2024 and 2025 will not be finalized; further instances could also be recognized as investigations proceed.”
They conclude, “Collaborative efforts in New York led to well timed identification of this emergent substance and enabled overdose prevention responses, prioritizing hurt discount companies and speedy dissemination of information to public and medical audiences.”
